Special Issue

Rapid Antibiotic Susceptibility Testing

Message from the Guest Editors

The main reason behind the development of multi-drug-resistant bacteria is the long duration required for laboratory results to determine bacterial antibiotic susceptibility. Hence, the rapid identification of bacterial antibiotic resistance is crucial. Rapid approaches have a high impact on multiple fronts, including ensuring timely and potentially life-saving treatment for patients, limiting the development and spread of multi-drug-resistant bacteria, and reducing the duration of illness and treatment. This, in turn, helps lower healthcare costs and eases the economic burden on families and society. This Special Issue extends an invitation for original research articles and reviews, seeking to collate a comprehensive collection of papers on efficient methodologies for determining antimicrobial susceptibility. The goal is to showcase advancements that revolutionize our ability to promptly and accurately identify antibiotic resistance, fostering a more effective and efficient approach toward bacterial infection management.

Guest Editors

Prof. Dr. Ahmad Salman
Shamoon College of Engineering, Beer Sheba, Israel

Prof. Dr. Itshak Lapidot
Afeka Tel Aviv Academic College of Engineering, Tel Aviv-Yafo, Israel

Deadline for manuscript submissions

15 April 2025

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed

mdpi.com/si/193333

Antibiotics
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI